These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 35706397)
1. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway. Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397 [TBL] [Abstract][Full Text] [Related]
2. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis. Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin. Wang X; Zhang F; Wu XR Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811 [TBL] [Abstract][Full Text] [Related]
4. Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer. Sha L; Lv Z; Liu Y; Zhang Y; Sui X; Wang T; Zhang H Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34109434 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of miR-214 inhibits proliferation and glycolysis in non-small-cell lung cancer cells via down-regulating the expression of hexokinase 2 and pyruvate kinase isozyme M2. Zhang K; Zhang M; Jiang H; Liu F; Liu H; Li Y Biomed Pharmacother; 2018 Sep; 105():545-552. PubMed ID: 29886375 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Wang D; Zhao C; Xu F; Zhang A; Jin M; Zhang K; Liu L; Hua Q; Zhao J; Liu J; Yang H; Huang G Theranostics; 2021; 11(6):2860-2875. PubMed ID: 33456577 [TBL] [Abstract][Full Text] [Related]
7. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121 [TBL] [Abstract][Full Text] [Related]
8. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line. Yang W; Liu J; Hou L; Chen Q; Liu Y Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292 [TBL] [Abstract][Full Text] [Related]
9. Apoptin Inhibits Glycolysis and Regulates Autophagy by Targeting Pyruvate Kinase M2 (PKM2) in Lung Cancer A549 Cells. Song G; Shang C; Zhu Y; Xiu Z; Li Y; Yang X; Ge C; Han J; Jin N; Li Y; Li X; Fang J Curr Cancer Drug Targets; 2024; 24(4):411-424. PubMed ID: 36284386 [TBL] [Abstract][Full Text] [Related]
10. PKM2/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism. Lin H; Han H; Yang M; Wen Z; Chen Q; Ma Y; Wang X; Wang C; Yin T; Wang X; Lu G; Chen H; Qi J; Yang Y Eur J Med Chem; 2023 Mar; 249():115166. PubMed ID: 36731272 [TBL] [Abstract][Full Text] [Related]
11. PKM2-dependent glycolysis promotes the proliferation and migration of vascular smooth muscle cells during atherosclerosis. Zhao X; Tan F; Cao X; Cao Z; Li B; Shen Z; Tian Y Acta Biochim Biophys Sin (Shanghai); 2020 Jan; 52(1):9-17. PubMed ID: 31867609 [TBL] [Abstract][Full Text] [Related]
12. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation. Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853 [No Abstract] [Full Text] [Related]
13. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway. Zhang J; Zhou J; Xiao S Anticancer Drugs; 2020 Oct; 31(9):932-941. PubMed ID: 32282369 [TBL] [Abstract][Full Text] [Related]
14. Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease. Chen Y; Bai X; Chen J; Huang M; Hong Q; Ouyang Q; Sun X; Zhang Y; Liu J; Wang X; Wu L; Chen X Cell Prolif; 2024 Feb; 57(2):e13548. PubMed ID: 37749923 [TBL] [Abstract][Full Text] [Related]
15. PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis. Wang Y; Hao F; Nan Y; Qu L; Na W; Jia C; Chen X Int J Biol Sci; 2018; 14(13):1883-1891. PubMed ID: 30443191 [TBL] [Abstract][Full Text] [Related]
16. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression. Zhao H; Jiang R; Feng Z; Wang X; Zhang C J Transl Med; 2023 Nov; 21(1):833. PubMed ID: 37980488 [TBL] [Abstract][Full Text] [Related]
17. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice. Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. Zhang H; Wang D; Li M; Plecitá-Hlavatá L; D'Alessandro A; Tauber J; Riddle S; Kumar S; Flockton A; McKeon BA; Frid MG; Reisz JA; Caruso P; El Kasmi KC; Ježek P; Morrell NW; Hu CJ; Stenmark KR Circulation; 2017 Dec; 136(25):2468-2485. PubMed ID: 28972001 [TBL] [Abstract][Full Text] [Related]
19. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells. Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094 [TBL] [Abstract][Full Text] [Related]
20. Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2. Liu T; Li S; Wu L; Yu Q; Li J; Feng J; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C J Hepatocell Carcinoma; 2020; 7():19-31. PubMed ID: 32110554 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]